Cancers, Vol. 13, Pages 5164: Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity

Cancers, Vol. 13, Pages 5164: Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity Cancers doi: 10.3390/cancers13205164 Authors: Marialuisa Piccolo Maria Grazia Ferraro Federica Raucci Claudia Riccardi Anella Saviano Irene Russo Krauss Marco Trifuoggi Michele Caraglia Luigi Paduano Daniela Montesarchio Francesco Maione Gabriella Misso Rita Santamaria Carlo Irace Selectivity and efficacy towards target cancer cells, as well as biocompatibility, are current challenges of advanced chemotherapy powering the discovery of unconventional metal-based drugs and the search for novel therapeutic approaches. Among second-generation metal-based chemotherapeutics, ruthenium complexes have demonstrated promising anticancer activity coupled to minimal toxicity profiles and peculiar biochemical features. In this context, our research group has recently focused on a bioactive Ru(III) complex—named AziRu—incorporated into a suite of ad hoc designed nucleolipid nanosystems to ensure its chemical stability and delivery. Indeed, we proved that the structure and properties of decorated nucleolipids can have a major impact on the anticancer activity of the ruthenium core. Moving in this direction, here we describe a preclinical study performed by a mouse xenograft model of human breast cancer to establish safety and efficacy in vivo of a cationic Ru(III)-...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research